Table 3—

Direct, indirect and total costs (NOK) per patient during a 12 month follow-up for the intervention and control groups

 Control Intervention p-value Mean±sd Median 25/75 P Mean±sd Median 25/75 P Cost items Patient education programme 0 0 900±50 900 (900/1000) <0.001 Peak flow meter 0 0 200 200 <0.001 Pharmaceuticals/drugs 3300±3100 2400 (1900/4500) 3700±3400 2400 (1000/5600) 0.703 GP visits 600±900 200 (0/800) 200±500 0 (0/200) 0.001 Pulmonary physician visits 55±200 0 (0/0) 52±200 0 (0/0) 0.555 Hospital admissions 0 0 700±2700 0 (0/0) 0.116 Travel costs doctor visits 63±89 22 (0/88) 21±55 0 (0/22) 0.001 Travel costs educational programme 0 0 100±34 100 (100/100) <0.001 Total direct costs 4000±3800 3400 (1100/5500) 5900±4800 4100 (2500/8800) 0.054 Patient time cost for education programme 0 0 1200±600 1400 (1100/1400) <0.001 Patient time cost for doctor visits 300±700 0 (0/200) 100±500 0 (0/0) 0.044 Production loss 11600±33100 0 (0/5100) 3400±16700 0 (0/0) 0.038 Total indirect costs 11900±33500 200 (0/6400) 4600±17300 1400 (1100/1500) 0.302 Total costs 16000±35400 5400 (1500/11100) 10500±20500 5800 (4000/10100) 0.510
• Both cost items and sums are, if NOK >100, rounded off to nearest NOK 100. *Mann-Whitney U-test

• 25/75 P=25th and 75th percentiles

• The mean number of GP visits, pulmonary physician visits and days off work in the control group were 2.6, 0.2 and 20.5, respectively. The corresponding figures for the intervention group were 0.7, 0.2 and 6.0 17. Median values with 25th and 75th percentiles are shown due to the skewed distribution of data. Time costs include travel time and are only calculated for those being employed, but alternative assumptions are explored through sensitivity analysis

• Control: n=39

• Intervention: n=32